The Longevity Reality Radar
46 approaches, rated by evidence.

mRNA vaccine for pancreatic cancer

Personalized mRNA cancer vaccine (autogene cevumeran) — pancreatic. Cancer. Reviewed Jul 2026.

Nearly 90% of patients whose immune system responded were alive up to six years later in a small early trial, and randomised survival results have not been reported.

Stage
Phase 1/2, pancreatic cancer
Rung: In human trials. Phase 1 to 3. Being tested in people now. Most will not make it.
Evidence grade
C
small early trial
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

A personalized mRNA vaccine (BioNTech/MSK) that teaches the immune system to recognize each patient's specific tumor mutations.

The evidence

Nearly 90% of patients whose immune systems responded to the vaccine were still alive up to six years after the last dose in early follow-up.

What you can do today

Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.

Sources

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Cancer

All 9 in Cancer.

  • Pelareorep for pancreatic cancerGrade C, response rates only. Phase 3, pancreatic cancer.Response rates in later-line settings beat the approved comparator, but that is not randomised survival data and the Phase 3 has not reported.
  • mRNA-4157 melanoma vaccineGrade B, Phase 3 unpublished. Phase 3, positive topline.Phase 3 beat Keytruda alone on recurrence, but only a press release exists, hazard ratios are unpublished and overall survival is immature.
  • CAR-T for solid tumoursGrade C, early responses. Phase 1/2.Encouraging early responses in gastric and some childhood tumours, but it is not curative for most solid cancers.
  • Creatine and cancer immunotherapyGrade D, mouse study. Preclinical.Improved anti-tumour immune signalling in mouse melanoma and has not been tested in people with cancer.
  • CRISPR-Cas12a2 for p53 cancersGrade D, lab only. Preclinical, lab only.Selectively killed p53-mutant cells in the lab, and nobody yet knows how to deliver it to every tumour cell in a living body.
  • Ivermectin for cancerGrade D, case reports. Preclinical, case reports.Lab and mouse data plus uncontrolled case reports, no controlled human trial, and self-treating melanoma risks a fatal delay.